Diabetes Mellitus and Heart Failure.
Wun-Zhih SiaoYong-Hsin ChenChin-Feng TsaiChun-Ming LeeGwo-Ping JongPublished in: Journal of personalized medicine (2022)
The coexistence of diabetes mellitus (DM) and heart failure (HF) is frequent and is associated with a higher risk of hospitalization for HF and all-cause and cardiovascular mortality. It has been estimated that millions of people are affected by HF and DM, and the prevalence of both conditions has increased over time. Concomitant HF and diabetes confer a worse prognosis than each alone; therefore, managing DM care is critical for preventing HF. This article reviews the prevalence of HF and diabetes and the correlated prognosis as well as provides a basic understanding of diabetic cardiomyopathy, including its pathophysiology, focusing on the relationship between DM and HF with a preserved ejection fraction and summarizes the potential aldosterone and the mineralocorticoid receptor antagonists approaches for managing heart failure and DM. Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) are an emerging class of glucose-lowering drugs, and the role of SGLT2Is in DM patients with HF was reviewed to establish updated and comprehensive concepts for improving optimal medical care in clinical practice.
Keyphrases
- acute heart failure
- heart failure
- glycemic control
- type diabetes
- ejection fraction
- risk factors
- blood glucose
- clinical practice
- cardiovascular disease
- healthcare
- aortic stenosis
- atrial fibrillation
- insulin resistance
- blood pressure
- angiotensin ii
- weight loss
- health insurance
- pain management
- wound healing
- affordable care act